# Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/quantifying-absolute-benefit-for-adjuvant-treatment-options-in-renal-cell/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Irbaz Bin Riaz,Qurat Ul Ain Riaz Sipra,Syed Arsalan Ahmed Naqvi,Huan He,Rabbia Siddiqi,Mahnoor Islam,Noureen Asghar,Waleed Ikram,Wenxin Xu,Hongfong Liu,Parminder Singh,Thai H. Ho,Mehmet Asım Bilen,Yousef Zakharia,Alan H. Bryce,M. Hassan Murad |
| Citations | 7 |
| DOI | 10.1016/j.critrevonc.2022.103706 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4229008167 |
| PMID | 35537621 |
| Type | review |
| Year | 2022 |

## Paper authors

- [Noureen Asghar](https://scholariq.org/researchers/noureen-asghar/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.